Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| moderate |
LUCENTIS 10 mg/mL, solution for injection provides a moderate improvement in actual benefit (level III) in terms of efficacy in comparison with VISUDYNE in the treatment of visual impairment due to choroidal neovascularisation secondary to pathologic myopia. |
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
g6EQz49Mupu24quN
